---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-25-000071"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:35:56.462374+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Keros discontinues cibotercept development, prioritizes KER-065; CEO becomes President, COO departs

## Summary
- Discontinuing all internal development of cibotercept (KER-012) after PAH trial termination.
- Exclusively prioritizing KER-065 for Duchenne muscular dystrophy; Phase 2 expected Q1 2026.
- CEO Jasbir Seehra adds President role effective Aug 18, 2025; steps down as Board Chair.
- Jean-Jacques Bienaimé appointed Chair of the Board, effective Aug 18, 2025.
- COO Christopher Rovaldi to depart Aug 18; Lorena Lerner promoted to CSO; SVP roles eliminated.

## SEC filing metadata
- accession: 0001664710-25-000071
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000071/0001664710-25-000071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000071/kros-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-25-000071
- JSON: https://secwatch.observer/filing/0001664710-25-000071.json
- Plain text: https://secwatch.observer/filing/0001664710-25-000071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.